Cortistatin-14: brain peptide that promotes deep sleep and protects nerves

What this is

Cortistatin-14 (CST-14) is a 14-amino acid neuropeptide produced in the mammalian central nervous system from the CORT gene — a gene distinct from the SST gene that encodes somatostatin, despite the two peptides sharing 11 of 14 residues and binding the same receptor family. Cortistatin was named for its expression in the CORTex and its structural relationship to somaToSTATIN. The CORT gene encodes preprocortistatin, which is proteolytically processed to yield a 29-residue storage form (CST-29), a 17-residue active form in humans (CST-17: DRMPCKNFFWKTFSSCK), and the C-terminal 14-residue isoform (CST-14) that corresponds to the rat discovery peptide. The stored sequence PCKNFFWKTFSSCK is canonical human CST-14 — the rat CST-14 studied in the original 1996 discovery paper differs at position 3 (Arg in rat vs Lys in human), a standard cross-species substitution rather than a modification or database error.

Cortistatin-14 binds all five somatostatin receptor subtypes (SST1–5) and additionally activates the growth hormone secretagogue receptor (GHSR) — a binding profile not shared by somatostatin. It is an endogenous neuropeptide with no approved clinical indication; all evidence is from animal models and in vitro systems.

History

Cortistatin was discovered in 1996 by Luis de Lecea, J. Gregor Sutcliffe, and colleagues at The Scripps Research Institute using subtractive hybridization of rat cerebral cortex mRNA. The discovery paper (de Lecea 1996) identified a novel neuropeptide transcript expressed in cortical interneurons that shared strong sequence homology with somatostatin-14 but arose from a distinct gene on a different chromosomal locus. The rat form is a 14-amino acid peptide (cortistatin-14, CST-14). In the same publication, the authors demonstrated that intracerebroventricular injection of CST-14 in rats produced behavioral quiescence and enhanced slow-wave sleep — effects distinct from those of somatostatin — suggesting a dedicated functional role in cortical sleep–wake regulation.

In humans, the CORT gene (chromosome 1p36.3) encodes a 115-amino acid preprocortistatin. The dominant mature forms in human brain are CST-17 and CST-29; CST-14 in humans represents the C-terminal fragment of CST-17 and is active at somatostatin receptors.

Over the following decade, cortistatin attracted attention for roles beyond sleep: researchers characterized extensive anti-inflammatory and immunomodulatory properties of cortistatin in macrophages, T cells, and animal models of inflammation, generating interest in its potential as a therapeutic scaffold for autoimmune and inflammatory diseases. As of 2026, cortistatin has no approved clinical use, though analogs with improved stability are under investigation.

What it does

Somatostatin receptor agonism: Cortistatin-14 binds SST1, SST2, SST3, SST4, and SST5 with low-nanomolar affinity, somewhat below that of somatostatin-14 at the same receptors. The downstream signaling — inhibition of adenylyl cyclase via Gi/Go proteins, activation of inward-rectifying K⁺ channels, inhibition of voltage-gated Ca²⁺ channels — is qualitatively similar to somatostatin. This shared receptor profile explains the overlap in effects on cortical excitability, neuroendocrine secretion, and GI smooth muscle that the two peptides share.

GHSR agonism (unique to cortistatin): Unlike somatostatin, cortistatin-14 activates the growth hormone secretagogue receptor (GHSR, ghrelin receptor) at micromolar concentrations. This activity drives release of growth hormone in vivo by a GHRH-like mechanism, producing GH elevations that somatostatin would inhibit. This pharmacological distinction has physiological relevance: in adult rat brain, intracerebroventricular cortistatin increases GH plasma levels via GHSR engagement, while somatostatin suppresses GH release. The GHSR activation by cortistatin may contribute to the sleep-associated GH pulses seen during slow-wave sleep.

Sleep modulation: Cortistatin's most studied behavioral effect is promotion of slow-wave sleep (non-REM sleep, NREM). Intracerebroventricular injection of cortistatin-14 in rats increases total NREM sleep time and deepens sleep architecture (increased slow-wave activity on EEG). This effect is mediated in part through cortical interneuron hyperpolarization — cortistatin hyperpolarizes neocortical pyramidal neurons by activating SST receptor-coupled GIRK channels, suppressing cortical excitability and favoring the synchronous low-frequency oscillations characteristic of NREM sleep. Somatostatin produces inconsistent effects on sleep in rats and minimal effects in humans; cortistatin's sleep-promoting action is considered a distinguishing functional property.

Anticonvulsant and neuroprotective effects: In kainic acid rat models of epilepsy, cortistatin-14 injection reduces the severity and duration of limbic seizures, and substantially reduces kainic acid-induced cell death in cortical and hippocampal neurons. Cortistatin is highly expressed in the immature rat brain (where it is upregulated after seizures) and is thought to contribute to the relative seizure resistance of the developing brain. In adult rats, cortistatin mRNA does not significantly upregulate after kainic acid-induced seizures, whereas somatostatin mRNA does — evidence that CORT and SST genes are transcriptionally regulated by distinct stimuli.

Anti-inflammatory and immunomodulatory effects: Cortistatin inhibits the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12) from activated macrophages and dendritic cells, and promotes an anti-inflammatory cytokine profile. In mouse models of Crohn's disease, sepsis, and arthritic inflammation, cortistatin administration reduced inflammatory pathology. The mechanisms involve both SST receptor signaling in immune cells and GHSR-independent direct effects. The unique distribution of CORT mRNA in cortical and hippocampal GABAergic interneurons — partially overlapping but distinct from SST-expressing interneurons — suggests a dedicated neuroimmune signaling role not fully covered by somatostatin.

Evidence

• Human: No human interventional trials of cortistatin-14 or related cortistatin peptides have been registered or published. ClinicalTrials.gov searches for "cortistatin" return studies of sST2 (soluble ST2, a cardiac biomarker protein unrelated to the cortistatin neuropeptide) rather than trials of the peptide itself.

• Animal: De Lecea and colleagues (1996) demonstrated that intracerebroventricular injection of CST-14 in rats produced behavioral sedation, enhanced slow-wave sleep, and anticonvulsant effects — blocked by somatostatin receptor antagonists. Neuroprotective effects against kainic acid-induced neuronal cell death in cortex and hippocampus have been documented in rat models, as reviewed by Clynen and colleagues (2014). Differential transcriptional regulation of CORT vs SST genes after seizure induction in adult and immature rats has also been documented (Clynen 2014).

• In vitro: Cortistatin-14 has been shown to activate all five SST receptor subtypes and additionally engage GHSR, a pharmacological profile distinguishing it from somatostatin (de Lecea 1996; Clynen 2014).

Myths and misconceptions

• "Cortistatin is just another form of somatostatin." The two peptides share 11 of 14 residues in their active cores and bind the same receptor family, but they arise from distinct genes (CORT on chromosome 1p36.3, SST on chromosome 3q28), are expressed in partially non-overlapping neuronal populations, are regulated by different transcriptional stimuli, and have divergent pharmacological profiles — specifically, cortistatin activates GHSR and promotes GH release, while somatostatin inhibits it. Calling cortistatin a "somatostatin variant" misses its independent biology.

• "The stored human CST-14 sequence is a variant because it differs from the de Lecea 1996 rat peptide." The position-3 Lys (human) vs Arg (rat) difference is a standard inter-species amino acid substitution, not a modification or database error. The stored sequence PCKNFFWKTFSSCK is canonical human CST-14 — the C-terminal 14 residues of human CST-17. Rat cortistatin-14 (PCRNFFWKTFSSCK) has Arg at that position because the rat CORT gene sequence differs from human CORT at that codon. Both are canonical sequences for their respective species.

• "Cortistatin has no clinical interest because it behaves like somatostatin." Its unique GHSR agonism, selective cortical/hippocampal expression, anti-inflammatory properties distinct from somatostatin-based analogs, and neuroprotective effects in seizure models make it an active area of drug-discovery interest. Stable cortistatin analogs have been explored as immunomodulatory leads for autoimmune disease, separate from the extensive somatostatin analog pharmacology (octreotide, lanreotide, and related compounds).

Common questions

Q: If cortistatin and somatostatin bind the same receptors, what distinguishes their effects in vivo? A: Several factors create distinct functional profiles. First, their expression patterns differ: somatostatin is expressed broadly in brain and peripheral tissues (GI, pancreas), while cortistatin expression is concentrated in cortical and hippocampal interneurons with more restricted distribution. Second, cortistatin uniquely activates GHSR, creating effects (GH stimulation, orexigenic signaling modulation) absent for somatostatin. Third, their transcriptional regulation differs — CORT and SST promoters respond to different transcription factors, so their release patterns under physiological stimuli can diverge. Fourth, their binding affinities across SST1–5 subtypes, while qualitatively similar, differ quantitatively, meaning that at physiological concentrations the receptor subtype occupancy profiles may differ.

Q: Why does cortistatin promote sleep while somatostatin does not consistently do so? A: The sleep-promoting effect of cortistatin is thought to involve two components: (1) direct hyperpolarization of cortical pyramidal neurons via SST receptor-coupled GIRK channel activation, reducing excitatory tone in the cortex and favoring slow-wave oscillations; and (2) GHSR-mediated GH release, since GH secretion and slow-wave sleep are physiologically coupled (the largest GH pulse of the day occurs during the first slow-wave sleep episode). Somatostatin, which inhibits rather than activates GHSR, cannot provide the GHSR component. The species and contextual inconsistency of somatostatin's sleep effects in published studies (some enhancement of REM, some no effect) contrasts with the more consistent NREM-promoting profile of cortistatin.

Q: Has cortistatin been tested as a treatment in humans? A: As of 2026, cortistatin itself has not entered human clinical trials as a therapeutic agent. The cortistatin neuropeptide faces the typical challenges of CNS peptide drug development: poor blood–brain barrier penetration, rapid enzymatic degradation in plasma, and the need for stable analogs. Preclinical interest in cortistatin as an immunomodulatory scaffold continues.

Related peptides

• Octreotide — the clinically approved somatostatin analog that binds SST2/SST5 and is used in acromegaly and carcinoid syndrome; illustrates what SST-receptor pharmacology looks like when translated to a pharmaceutical
• Secretin — another regulatory peptide with cortical expression and neural modulation functions, from a different precursor family
• Obestatin — a GHRL-gene-derived peptide with disputed receptor biology, contrasting with cortistatin's clear (though multiple) receptor interactions; both are examples of neuropeptides where initial receptor pharmacology reports required significant subsequent revision